Skip to main
FULC
FULC logo

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 15%
Buy 38%
Hold 38%
Sell 8%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics Inc. has garnered increased enthusiasm for its pociredir program, particularly following the recent withdrawal of Oxbryta, which may enhance patient enrollment rates and rebuild trust within the community. The company has demonstrated resilience by successfully pivoting from a previous clinical hold and is now reporting promising early signs of clinical activity in its phase Ib study, including dose-dependent increases in fetal hemoglobin levels and improvements in biomarkers. Additionally, Fulcrum's commitment to maintaining a disciplined restructuring strategy and aligning with ESG principles positions it favorably for sustainable growth and value creation in the biopharmaceutical space.

Bears say

Fulcrum Therapeutics reports significant net losses, with $21.6 million in 3Q24 and $16.5 million in 4Q24, highlighting ongoing financial challenges. The clinical development of losmapimod has faced setbacks, including a failure to meet primary endpoints in the Phase III REACH trial, raising concerns about the efficacy of its lead product. Additionally, risks associated with the pociredir compound in clinical studies could further diminish the company's market value, potentially reducing its stock to a level that reflects only its net cash position.

FULC has been analyzed by 13 analysts, with a consensus rating of Buy. 15% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Buy based on their latest research and market trends.

According to 13 analysts, FULC has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.